نتایج جستجو برای: ژن pik3ca

تعداد نتایج: 18195  

Journal: :American journal of cancer research 2015
Nandini Dey Brian Leyland-Jones Pradip De

Approximately 35% of breast cancers exhibit PIK3CA activating mutation. Since PIK3CA hotspot mutation is the most frequently mutated gene in human breast cancers and primarily overlaps in HER2+ as well as ER+ breast cancers, the subset of patients bearing PIK3CA activating mutation does not get fullest benefit from either anti-HER2 or anti-hormonal agents. Literature also suggests that these pa...

2012
Giovanni Brandi Simona Tavolari Francesco De Rosa Stefania Di Girolamo Valentina Agostini Maria Aurelia Barbera Giorgio Frega Guido Biasco

The employment of anti-epidermal growth factor receptor (EGFR) antibodies represents a backbone of the therapeutic options for the treatment of metastatic colorectal cancer (mCRC). However, this therapy is poorly effective or ineffective in unselected patients. Mutations in KRAS, BRAF and PIK3CA genes have recently emerged as the best predictive factors of low/absent response to EGFR-targeted t...

2010
Stefano Barbi Ivana Cataldo Giovanni De Manzoni Samantha Bersani Simona Lamba Silvia Mattuzzi Alberto Bardelli Aldo Scarpa

BACKGROUND PIK3CA is one of the genes most frequently mutated in human cancers and it is a potential target for personalized therapy. The aim of this study was to assess the frequency and type of PIK3CA mutations in gastric carcinoma and compare them with their clinical pathological correlates. METHODS We analysed 264 gastric cancers, including 39 with microsatellite instability (MSI), for mu...

Journal: :British journal of haematology 2014
Claudia Hofmann Thorsten Stühmer Nadine Schmiedl Reinhard Wetzker Anja Mottok Andreas Rosenwald Christian Langer Josip Zovko Manik Chatterjee Hermann Einsele Ralf C Bargou Torsten Steinbrunn

Constitutive phosphatidylinositide 3-kinase (PI3K) signalling has been implicated in multiple myeloma (MM) pathophysiology and is regarded as an actionable target for pharmacological intervention. Isoform-specific PI3K inhibition may offer the most focused treatment approach and could result in greater clinical efficacy and reduced side effects. We therefore performed isoform-specific knockdown...

2013
Heesue Kim Cheol-Keun Park Su Jin Lee Sun Young Rha Kyu Hyun Park Ho Yeong Lim

PURPOSE Phosphatidylinositol 3-kinases/AKT pathway plays a pivotal role in hepatocellular carcinoma (HCC). Mutant PIK3CA, encoding the p110a catalytic subunit, stimulates the AKT pathway and promotes cell growth in various cancers. PIK3CA mutation rate has been usually reported as low frequency (<5%) in HCC except one report from Korea with 35.6%. Therefore, we investigated the frequency of PIK...

Journal: :Cancer research 2008
Katsutoshi Oda Jennifer Okada Luika Timmerman Pablo Rodriguez-Viciana David Stokoe Keiko Shoji Yuji Taketani Hiroyuki Kuramoto Zachary A Knight Kevan M Shokat Frank McCormick

Mutations in genes functioning in different pathways frequently occur together in the same cancer, whereas mutations in the same pathway tend to be mutually exclusive. However, the majority of colon, breast, and endometrial cancers that possess mutations in PIK3CA, the catalytic subunit p110alpha of phosphatidylinositol 3'-kinase (PI3K), also possess mutations or alterations in genes upstream o...

Journal: :Cancer research 2013
Grace M Wang Hong Yuen Wong Hiroyuki Konishi Brian G Blair Abde M Abukhdeir John P Gustin D Marc Rosen Samuel Ray Denmeade Zeshaan Rasheed William Matsui Joseph P Garay Morassa Mohseni Michaela J Higgins Justin Cidado Danijela Jelovac Sarah Croessmann Rory L Cochran Sivasundaram Karnan Yuko Konishi Akinobu Ota Yoshitaka Hosokawa Pedram Argani Josh Lauring Ben Ho Park

The selective pressures leading to cancers with mutations in both KRAS and PIK3CA are unclear. Here, we show that somatic cell knockin of both KRAS G12V and oncogenic PIK3CA mutations in human breast epithelial cells results in cooperative activation of the phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways in vitro, and leads to tumor formation in immunocompr...

2014
Andrea Casadei Gardini Laura Capelli Paola Ulivi Massimo Giannini Eva Freier Stefano Tamberi Emanuela Scarpi Alassandro Passardi Wainer Zoli Angela Ragazzini Dino Amadori Giovanni Luca Frassineti

Anti-EGFR therapy appears to be a potential treatment option for squamous cell anal carcinoma (SCAC). KRAS mutation is a rare event in SCAC, indicating the absence of the principal mechanism of resistance to this type of therapy. However, no information is available from the literature regarding the status of BRAF or PIK3CA in this cancer type. We analysed KRAS, BRAF and PIK3CA status in SCAC p...

Journal: :Anticancer research 2009
Xiuju Sun Jian Huang Taku Homma Daisuke Kita Helmut Klocker Georg Schafer Peter Boyle Hiroko Ohgaki

Alterations in the PIK3CA and PTEN genes were assessed in 40 prostate tumors (radical prostatectomy samples). Genetic analyses in glands of the highest Gleason pattern within each tumor revealed PIK3CA amplification in 13%, PIK3CA mutations in 3%, PTEN homozygous deletion in 13% and PTEN hemizygous deletion in 8% of the cases analyzed. Supporting the view that PTEN and PIK3CA act in the same PI...

Journal: :Cancer research 2014
Yi-Zhou Jiang Ke-Da Yu Jing Bao Wen-Ting Peng Zhi-Ming Shao

We investigated the loss of somatic mutations in TP53 and PIK3CA in breast cancer tissue after neoadjuvant chemotherapy (NCT) and the clinical relevance of the observed mutation profiles. Samples were derived from three cohorts: Cohort 1 consisting of 206 patients undergoing NCT with matched pre- and postchemotherapy tumor tissues; Cohort 2 consisting of 158 additional patients undergoing NCT; ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید